Cost-Effectiveness Of Apixaban Compared To Other Anticoagulants For Lifetime Treatment And Prevention Of Recurrent Venous Thromboembolism von Lanitis, T, Hamilton, M, Rublee, D.A, Leipold, R, Quon, P, Browne, C, Cohen, A.T

Volltext

Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Prevention... von Hamilton, M, Phatak, H, Lanitis, T, Mardekian, J, Rublee, D.A, Leipold, R, Quon, P, Browne, C, Cohen, A.T

Volltext

Identification of determinants of progression to type 2 diabetes using electronic health records and ‘big data’ analytics von Anderson, J.P, Parikh, J.R, Shenfeld, D.K, Church, B.W, Laramie, J.M, Piper, B.A, Willke, R.J, Mardekian, J, Rublee, D.A

Volltext

PCV90 - Cost-Effectiveness Of Apixaban Compared To Other Anticoagulants For Lifetime Treatment And Prevention Of Recurrent Venous Thromboembolism von Lanitis, T., Hamilton, M., Rublee, D.A., Leipold, R., Quon, P., Browne, C., Cohen, A.T.

Volltext

PCV14 - Lifetime Clinical Events Avoided And Resource Utilization With Apixaban Compared To Low-Molecular-Weight Heparin Followed By A Vitamin K Antagonist For The Treatment And Pr... von Hamilton, M., Phatak, H., Lanitis, T., Mardekian, J., Rublee, D.A., Leipold, R., Quon, P., Browne, C., Cohen, A.T.

Volltext

PDB27 - Identification of determinants of progression to type 2 diabetes using electronic health records and ‘big data’ analytics von Anderson, J.P., Parikh, J.R., Shenfeld, D.K., Church, B.W., Laramie, J.M., Piper, B.A., Willke, R.J., Mardekian, J., Rublee, D.A.

Volltext